<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01589549</url>
  </required_header>
  <id_info>
    <org_study_id>2011/128</org_study_id>
    <secondary_id>CTN 2012/0174</secondary_id>
    <nct_id>NCT01589549</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stromal Cells for Acute Graft Versus Host Disease</brief_title>
  <official_title>A Phase 2 Trial of Standard of Care Treatment Versus Mesenchymal Stromal Cell Therapy Together With Standard of Care for the Treatment of de Novo Acute Graft Versus Host Disease Following Allogeneic Bone Marrow Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R.P.Herrmann</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Perth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Perth Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised study of corticosteroid therapy with or without mesenchymal stromal cell therapy
      for newly diagnosed acute graft versus host disease after bone marrow transplantation or
      donor lymphocyte therapy.

      It is hypothesised that mesenchymal stromal cell therapy will be superior
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with newly diagnosed untreated acute graft versus host disease grades 2-4 will
      receive methylprednisolone 2.5mg/kg intravenously and randomised to receive or not receive
      allogeneic human mesenchymal stromal cells 2X10E6 intravenously on two occasions at weekly
      intervals
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival at one year after onset of graft versus host disease</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response at 14 days after commencement of treatment for acute graft versus host disease</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response at 28 days after commencement of treatment of acute graft versus host disease</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe infection</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival at one year</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure, requiring salvage therapy</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Acute GVH Disease</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stromal cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mesenchymal stromal cell therapy in addition to corticosteroid therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal stromal cell therapy</intervention_name>
    <description>One arm will be randomised to receive mesenchymal stromal cell therapy in addition to corticosteroid therapy</description>
    <arm_group_label>Mesenchymal stromal cell therapy</arm_group_label>
    <arm_group_label>Corticosteroid therapy</arm_group_label>
    <other_name>Methylprednisolone</other_name>
    <other_name>Mesenchymal stem cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Grades 2-4 acute graft versus host disease after bone marrow transplantation up to day
             +180 after transplantation

          -  Age 18-55 years

               -  Must be receiving a calcineurin inhibitor

        Exclusion Criteria:

          -  Failure to sign informed consent

          -  Corticosteroid therapy for 72 hours or greater

          -  ECOG score equal to or greater than 3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duncan Purtill, MB, BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Perth Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Duncan Purtill, MB, BS</last_name>
    <phone>+61 8 61523788</phone>
    <email>duncan.purtill@health.gov.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Richard Herrmann, MB, BS</last_name>
    <phone>+61 8 92241987</phone>
    <email>richard.herrmann@health.wa.gov.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Margaria, BN</last_name>
      <phone>+61 8 92247038</phone>
      <email>megan.margaria@health.wa.gov.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2012</study_first_submitted>
  <study_first_submitted_qc>April 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2012</study_first_posted>
  <last_update_submitted>June 8, 2015</last_update_submitted>
  <last_update_submitted_qc>June 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Royal Perth Hospital</investigator_affiliation>
    <investigator_full_name>R.P.Herrmann</investigator_full_name>
    <investigator_title>Director, Cell and Tissue Therapies, Royal Perth Hospital</investigator_title>
  </responsible_party>
  <keyword>Acute graft versus host disease</keyword>
  <keyword>Bone marrow transplantation</keyword>
  <keyword>Mesenchymal stromal cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

